for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Recro Pharma Inc

REPH.OQ

Latest Trade

11.86USD

Change

0.02(+0.17%)

Volume

1,499

Today's Range

11.83

 - 

11.86

52 Week Range

5.55

 - 

12.66

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.84
Open
11.83
Volume
1,499
3M AVG Volume
4.09
Today's High
11.86
Today's Low
11.83
52 Week High
12.66
52 Week Low
5.55
Shares Out (MIL)
22.43
Market Cap (MIL)
265.54
Forward P/E
-19.57
Dividend (Yield %)
--

Latest Developments

More

Recro Pharma Q2 Loss Per Share $0.13

Recro Pharma Reports Q1 Loss Per Share Of $0.09

Recro Pharma Inc says Will Incur About $4 Mln Of Costs In Connection With Workforce Reduction

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Recro Pharma Inc

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Industry

Biotechnology & Drugs

Contact Info

490 Lapp Rd

+1.484.3952400

https://recropharma.com/

Executive Leadership

Wayne B. Weisman

Independent Chairman of the Board

Geraldine A. Henwood

President, Chief Executive Officer, Director

Ryan D. Lake

Chief Financial Officer

Jyrki Mattila

Executive Vice President - Business Development

Randall Mack

Senior Vice President - Development, Secretary

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-2.820

2017

-1.990

2018

-3.900

2019(E)

-0.605
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.87
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-41.81
Return on Equity (TTM)
-34.69

Latest News

Recro Pharma shares plummet after FDA rejects non-opioid pain shot

Recro Pharma's shares dropped more than 50 percent on Thursday after the U.S. Food and Drug Administration declined to approve the drugmaker's non-opioid shot IV meloxicam, saying the pain-relieving effect did not meet expectations.

BRIEF-Recro Pharma Receives Complete Response Letter From FDA

* RECRO PHARMA RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA

FDA declines to approve Recro Pharma's non-opioid pain shot

The U.S. Food and Drug Administration on Thursday declined to approve Recro Pharma's IV meloxicam noting the pain-relieving effect of the drug did not meet its expectations.

BRIEF-Recro Pharma Reports Q1 Loss Per Share Of $0.65

* Q1 EARNINGS PER SHARE VIEW $-0.70 -- THOMSON REUTERS I/B/E/S

BRIEF-Recro Pharma Announces Receipt Of Issue Notifications For Three New Patents For Iv Meloxicam

* RECRO PHARMA ANNOUNCES RECEIPT OF ISSUE NOTIFICATIONS FOR THREE NEW PATENTS FOR IV MELOXICAM Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma Inc Reports Year End 2017 Financial Results

* RECRO PHARMA INC - FOR 2018, COMPANY EXPECTS REVENUE GENERATED FROM ITS CDMO DIVISION TO BE APPROXIMATELY $70 MILLION

BRIEF-Recro Pharma Estimates Cash And Cash Equivalents About $64 Mln As Of Dec 31

* RECRO PHARMA - ESTIMATES THAT AS OF DEC 31, 2017, CASH AND CASH EQUIVALENTS WERE APPROXIMATELY $64.0 MILLION Source text for Eikon: (http://bit.ly/2nOPGN7) Further company coverage:

BRIEF-Recro Pharma - ‍Ryan Lake Promoted To CFO

* RECRO PHARMA INC - RYAN D. LAKE HAS BEEN PROMOTED TO CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma Says Entered Into A Sales Agreement With Cowen And Co

* RECRO PHARMA INC - ENTERED INTO A SALES AGREEMENT WITH COWEN AND COMPANY

BRIEF-Recro Pharma secures $100 million credit facility

* Recro Pharma Inc - has secured a $100 million credit facility from funds managed by Athyrium Capital Management, LP

BRIEF-Recro Pharma reports Q3 revenue $17.1 million

* Recro Pharma Inc - Raising its guidance for 2017 revenue from a range of $60-$63 million to $65 million

BRIEF-RECRO PHARMA ANNOUNCES PDUFA DATE OF MAY 26, 2018 FOR IV MELOXICAM 30MG

* RECRO PHARMA - U.S. FDA HAS SET A PDUFA DATE OF MAY 26, 2018 FOR ITS DECISION ON NEW DRUG APPLICATION (NDA) FOR INTRAVENOUS (IV) MELOXICAM 30MG Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg

* Recro Pharma announces FDA acceptance for review of new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Recro Pharma quarterly ‍loss per share $0.48

* Qtrly loss per share $0.48; Co is raising its guidance for 2017 revenue from a range of $55-$60 million to $60-$63 million Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma submits new drug application for IV Meloxicam 30mg

* Recro Pharma submits new drug application for IV Meloxicam 30mg Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma acquires Novel Neuromuscular blocking agents

* Says under terms of agreement, Recro Pharma will pay Cornell a six figure initial up-front fee

BRIEF-Recro Pharma files for mixed shelf of up to $100 mln - SEC Filing

* Recro pharma files for mixed shelf of up to $100 million - sec filing Source text for Eikon: Further company coverage:

BRIEF-Recro Pharma presents Phase III bunionectomy clinical data for IV meloxicam

* Recro Pharma presents Phase III bunionectomy clinical data for IV meloxicam at the American Pain Society 36th annual scientific meeting

BRIEF-Recro Pharma reports Q1 loss per share of $0.42

* Q1 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S

BRIEF-Recro Pharma announces successful top-line results from phase III safety study of iv meloxicam

* Recro pharma announces successful top-line results from phase iii safety study of iv meloxicam

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up